Catalysts ahead for the smaller players
Calliditas heads for confirmatory data in IgA nephropathy, while Viking and 89Bio are set for key readouts in Nash.
Remarkably, interest in BCMA continues
But, as Celyad bows out, how do you compete in a field as crowded as this?
Biotech’s key upcoming clinical results
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
Big pharma’s new year catalysts
In the opening months of 2023 Novo Nordisk needs to defend its position, while Daiichi and Astrazeneca await ADC data.
Ash 2022 movers – Glycomimetics shakes off its sickle cell past
Meanwhile, there was bad blood between cell therapy players and their investors.
Ash 2022 – pirtobrutinib leads the post-Imbruvica charge
Lilly’s non-covalent BTK inhibitor shines yet again, blunting the impact of early data with Nurix’s BTK degrader.
Ash 2022 – Orchard gets a Sanfilippo boost
Promising but early data with OTL-201 could see the group compete against the likes of Ultragenyx and Lysogene.
Ash 2022 – Affimed feels the pain
Affimed investors find that what goes up must come down, though the stock owes only part of its fall to an Ash presentation.
